These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 20172072)

  • 1. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
    Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
    Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
    Retina; 2007; 27(6):707-12. PubMed ID: 17621179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY; Chan WM; Liu DT; Lam DS
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choroidal neovascularization in pathologic myopia.
    Dave V; Narayanan R
    Am J Ophthalmol; 2010 Nov; 150(5):752; author reply 752-3. PubMed ID: 21036211
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
    Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D; Gad MA; Enam KM
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
    Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
    Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
    Sakaguchi H; Ikuno Y; Gomi F; Kamei M; Sawa M; Tsujikawa M; Oshima Y; Kusaka S; Tano Y
    Br J Ophthalmol; 2007 Feb; 91(2):161-5. PubMed ID: 16914470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study.
    Gharbiya M; Allievi F; Conflitti S; Esposito M; Scavella V; Moramarco A; Cruciani F
    Clin Ter; 2010; 161(3):e87-93. PubMed ID: 20589348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.